|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
3/15/2010 1:31:55 PM
15th March 2010: Tocris Bioscience (Bristol, UK) announced today that it has entered into an agreement with Pfizer which will result in a wide range of Pfizer compounds being made available to the global research community.
For the first time, scientists involved in preclinical research will now be able to purchase authentic, fully-licensed, non-formulated, sunitinib, varenicline and other Pfizer compounds as off-the shelf products for use in their preclinical research studies. In addition, a significant number of Pfizer's ‘literature compounds’ - biologically active small molecules that have not progressed from development to clinical use - will also be offered for sale.
Typically supplied in 10 and 50 milligram pack sizes ideally suited for preclinical laboratory research applications, the availability of these products through Tocris will benefit scientists working in a diverse range of fields, including neuroscience, cancer and metabolic disease.
"We are pleased to be working with Tocris" noted Richard Connell, VP of External Research Solutions CoE at Pfizer. "Tocris has an excellent track record of respecting Pfizer’s intellectual property while making a range of important compounds available to the research community. We appreciate the innovative and creative ways they listen to and serve life science researchers in academia and industry".
Laurence Ede, Tocris' Managing Director, added "Pfizer's portfolio of compounds is world class and I'm very excited that Tocris has the opportunity to provide preclinical researchers with access to these materials. These important new additions perfectly complement Tocris' range of high purity compounds, which are used by scientists worldwide in the furtherance of biomedical research. We are delighted to enter into this agreement with Pfizer and look forward to working in close partnership together going forward."
About Tocris
For over a quarter of a century Tocris Bioscience has been established as a leading supplier of innovative high performance life science research reagents, with customers throughout the world's pharmaceutical companies, universities and research institutes. Our range of over 3,000 life science reagents consists of small molecules, peptides and antibodies, and represents a unique collection of novel and exclusive research tools, including GPCR ligands, neurotransmitters, ion channel modulators, signaling inhibitors and much more. With our industry-leading quality, next day delivery and first-class technical support, Tocris is the first place to look for all your research needs. To learn more, please visit our website at www.tocris.com.
|
|
|
|
|
|
|
|
|
|
|